Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Aurobindo Pharma Limited
AUROPHARMA | NSE
1,225.50
INR30.10
2.52%
AUROPHARMA | NSE
About Aurobindo Pharma Limited
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
31/03/2024
As of date
05/03/2026
Close
1,225.50
Open
1,198.00
High
1,230.70
Low
1,198.00
Aurobindo Pharma Limited engages in the research development manufacture and sale of active pharmaceutical ingredients generic pharmaceuticals and related services in India. The company primarily offers oral solids injectables and over-the-counter drugs as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular central nervous system gastroenterology anti-allergies anti-diabetics anti-retroviral antibiotics dermatology respiratory and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition the company develops and manufactures peptides as well as biocatalysts for use in the pharmaceutical and chemical industries. Further it is developing biosimilar inhalers transdermal patches vaccines topicals and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad India.
View LessAUROPHARMA | NSE
Risk
39.0
Sharpe
0.19
Luna's Score
67/100
Recommendation
Buy
Luna says (AUROPHARMA | NSE)
What's Working
Low 6-Month Volatility (<30%)
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
Midcap (2B - 10B USD)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
27.2%1 month
39.0%3 months
30.5%6 months
26.9%Returns
Fundamental Ratios
PE
24.51
Fwd. PE
8.36
Price to book
2.86
Debt to equity
0.22
Debt to assets
0.15
Ent. to EBITDA
12.62
Ent. to rev.
2.92
PEG
-
Other Fundamentals
EBITDA
62.17B
MarketCap
711.77B
MarketCap(USD)
7.74B
Div. yield
0.31
Op. margin
16.06
Erngs. growth
61.10
Rev. growth
10.50
Ret. on equity
11.18
Short ratio
-
Short perc.
-
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
107.60
Range1M
144.90
Range3M
164.80
Volumes: Market Activity
Rel. volume
0.42
Price X volume
1.10B
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 12.62 | 24.85 | Cheaper |
| Ent. to Revenue | 2.92 | 11.40 | Cheaper |
| PE Ratio | 24.51 | 51.36 | Cheaper |
| Price to Book | 2.86 | 6.83 | Cheaper |
| Dividend Yield | 0.31 | 0.52 | Poor |
| Std. Deviation (3M) | 30.51 | 42.17 | Lower Risk |
| Debt to Equity | 0.22 | 0.35 | Cheaper |
| Debt to Assets | 0.15 | 0.17 | Par |
| Market Cap | 711.77B | 290.82B | Market Leader |
